MedTrace Logo

New York Blood Center National Cord Blood Program

NCT00212407 · Status: TERMINATED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 4476

Last updated 2018-11-02

No results posted yet for this study

Summary

Umbilical cord blood is used as a source of hematopoietic stem cells for bone marrow reconstitution in patients who would be potential candidates for a bone marrow transplant from an unrelated marrow donor. The outcome of transplantation is obtained to assess cord blood myeloid and platelet engraftment, transplant related mortality, overall survival, graft vs. host disease and, for patients with leukemia, lymphoma or myelodysplasia, relapse.

Conditions

Interventions

BIOLOGICAL

Umbilical Cord Blood Transplantation

Sponsors & Collaborators

  • New York Blood Center

    lead OTHER

Principal Investigators

  • Pablo Rubinstein, M.D. · New York Blood Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1993-02-28
Primary Completion
2011-11-10
Completion
2011-11-10

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00212407 on ClinicalTrials.gov